Medpace lands Ph III AMR101 trial contract

- Last updated on GMT

Related tags: Contract research organization

US specialist cardiovascular CRO Medpace will run Phase III trials of Amarin’s candidate triglyceride drug, AMR101.

Under the deal, announced yesterday, Cincinnati, Ohio based Medpace will run two trials of the drug in hypertriglyceridemia and mixed dyslipidemia, in support of Amarin’s efforts to gain Food and Drug Administration (FDA) approval sometime in 2012.

Amarin’s interim CEO, Declan Doogan, said that Medpace’s expertise in cardiovascular and metabolic disease studies as well as its regulatory knowledge was critical in winning the contract research organisation (CRO) the contract.

Dr Doogan added that: “We were also impressed by their international reach, an important requirement given that one of the Phase 3 trials with AMR101 will be conducted across a number of international regions​.”

Related news

Show more

Related products

show more

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars